Colleen S, Ek A, Gullberg B, Johansson B G, Lindberg L G, Olsson A M
Scand J Urol Nephrol. 1979;13(2):149-53. doi: 10.3109/00365597909181170.
The concentration of carcinoembryonic antigen (CEA) in urine and serum was determined repeatedly during one year in 213 patients followed because of previously treated urothelial carcinoma of the bladder. The findings were correlated to grade and stage of previously treated tumour, given therapy, recurrence and the cytological evaluation of a midstream urine specimen. During the period of follow up 43 recurrences were clinically observed. With the exception for the content of inflammatory cells no correlation was found between the CEA levels in urine or blood and the parameters studied. Thus CEA in urine and/or serum cannot substitute for cystourethroscopy, urography and exfoliative cytology in the follow-up of patients previously treated for urothelial carcinoma.
对213例因既往接受过膀胱尿路上皮癌治疗而接受随访的患者，在一年时间内多次测定其尿液和血清中癌胚抗原（CEA）的浓度。研究结果与既往治疗肿瘤的分级和分期、给予的治疗、复发情况以及中段尿标本的细胞学评估相关。在随访期间，临床观察到43例复发。除炎症细胞含量外，未发现尿液或血液中的CEA水平与所研究的参数之间存在相关性。因此，在既往接受过膀胱尿路上皮癌治疗的患者随访中，尿液和/或血清中的CEA不能替代膀胱尿道镜检查、尿路造影和脱落细胞学检查。
